Bernstein Maintains Their Buy Rating on Roche Holding AG (RHHVF)

Bernstein analyst Wimal Kapadia maintained a Buy rating on Roche Holding AG (RHHVF) yesterday and set a price target of CHF360.00. The company’s shares closed last Tuesday at $331.20.

According to, Kapadia is ranked #2818 out of 7404 analysts.

Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $369.79, implying an 11.0% upside from current levels. In a report issued on March 9, Citigroup also maintained a Buy rating on the stock with a CHF360.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $378.47 and a one-year low of $281.04. Currently, Roche Holding AG has an average volume of 6,077.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts